Investigation of the combination of anti-PD-L1 mAb with HER2/neu-loaded dendritic cells and QS-21 saponin adjuvant: effect against HER2 positive breast cancer in mice.

Immunopharmacology and Immunotoxicology
Cenk Serhan ÖzverelAyse Nalbantsoy

Abstract

Human epidermal growth factor receptor 2 (HER2) is overexpressed in a subset of cancers including 25% of breast cancers. Since combination therapy consisting of multiple therapeutic approaches is considered a promising regimen, we examined combination treatment modalities in a xenograft model in Balb/c mice injected with 4T1-HER2 cells. We used HER2/neu-loaded bone marrow-derived dendritic cells (BM-DC's) along with anti-PD-L1 monoclonal antibody in a new combination immunotherapy model. The combination was composed of an active immunotherapy (i.e. BM-DC-based vaccine) designed to boost the immune response against target antigen and was augmented by using anti-PD-L1 mAb to prevent immune evasion by the xenografted tumors. The vaccine combination was further supported using a QS-21 saponin adjuvant and the immune response was evaluated. Mice treated with HER2/neu-loaded BM-DCs, combined with QS-21 and anti-PD-L1 mAb had significantly decreased tumor sizes and their splenocytes had enhanced cytotoxic activity, based on the lactate dehydrogenase (LDH) assay, compared to vaccine and adjuvant groups alone. The same vaccination group demonstrated a remarkable increase in IFN-γ secreting CD8+ T-cells analyzed by flow cytometry. ELISA ...Continue Reading

References

Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P C Roche, J N Ingle
Jul 16, 2003·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Jin-Shing ChenMien-Chie Hung
Jul 22, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Michael H KershawPhillip K Darcy
May 30, 2006·Advances in Immunology·Alan J KormanJames P Allison
Feb 8, 2011·Journal of Ethnopharmacology·Ayşe NalbantsoyErdal Bedir
Jan 24, 2014·Breast Cancer Research : BCR·Carla De GiovanniPier-Luigi Lollini
Jul 24, 2015·JAMA Oncology·Mark M Moasser, Ian E Krop
Mar 24, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thi TranEric Tartour
Sep 17, 2016·Human Vaccines & Immunotherapeutics·Nathalie Garçon, Alberta Di Pasquale
Mar 7, 2017·Therapeutics and Clinical Risk Management·Alexander D LeNinh M La-Beck
Aug 23, 2017·Cancer Letters·Mengyu FengYupei Zhao
Oct 11, 2017·Seminars in Cancer Biology·Samantha BuruguTorsten O Nielsen
Jan 10, 2018·The Journal of Immunology : Official Journal of the American Association of Immunologists·Olivera J Finn
Feb 14, 2018·Biochemical and Biophysical Research Communications·Wangqian ZhangCun Zhang
Apr 25, 2018·Nature Medicine·Mikhail BinnewiesMatthew F Krummel
May 29, 2018·Journal of Cancer·Hongming Zhang, Jibei Chen
Jun 7, 2018·Cancer Biotherapy & Radiopharmaceuticals·Naipeng CuiChuanwei Yang
Jan 5, 2019·Journal of breast cancer·Adil AllahverdiyevEmrah Sefik Abamor

❮ Previous
Next ❯

Citations

Aug 22, 2021·Immunology Letters·Muzaffer YildirimIhsan Gursel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Antigenic Modulation

Antigenic modulation occurs when an antibody cross-links antigens on a cell surface, causing the antigens to become internalized. This can lead to therapeutic failure of monoclonal antibodies as the expression of the antigen becomes decreased on target cells. Find the latest research on antigenic modulation here.